E2F1 and cancer: Avasimibe could also suppress PCa cell proliferation by downregulating the expression of low-density lipoprotein receptors and decreasing low-density lipoprotein uptake [9]; this is also one of the pathways through which the E2F-1 protein exerts its anti-cancer effects.